Jacobio Pharma Signs Agreement With AstraZeneca On Pan-KRAS Inhibitor JAB-23E73
I'm PortAI, I can summarize articles.
Jacobio Pharma has signed a strategic agreement with AstraZeneca for its Pan-KRAS inhibitor, JAB-23E73. AstraZeneca gains exclusive rights outside China, while both companies will collaborate within China. Jacobio receives $100 million upfront and potential milestone payments up to $1.915 billion. AstraZeneca will handle development and commercialization outside China. JAB-23E73 targets KRAS mutations, currently in Phase I trials. Jacobio plans further KRAS pathway exploration and immuno-oncology programs.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: rttnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments